Excitotoxicity in ALS

Neurology

Volumn 47, Issue 6 SUPPL. 4, 1996, Pages

  Leigh, P Nigel ^a   Meldrum, Brian S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; EXCITATORY AMINO ACID RECEPTOR; EXCITOTOXIN; GLUTAMATE RECEPTOR; GLUTAMIC ACID; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AMYOTROPHIC LATERAL SCLEROSIS; CALCIUM TRANSPORT; HUMAN; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; SODIUM TRANSPORT;

EID: 0029732866     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.47.6_suppl_4.221s     Document Type: Review

References (87)

1. Lucas DR, Newhouse JP. The toxic effects of sodium-L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol 1957;58:193-204.
2. Olney JW, Ho OL, Rhee V. Cytotoxic effects of acidic amino acids on the infant mouse central nervous system. Exp Brain Res 1971;14:61-76.
3. Adams ME, Swanson G. Neurotoxins. Trends Neurosci 1996;19(suppl):22-23.
4. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622.
5. Malessa S, Leigh PN. Neurochemistry of motor neurone disease. In: Swash M, Leigh PN, eds. Motor neurone disease. London: Springer-Verlag, 1995:163-188.
6. Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995;68:7-20.
7. Shaw P. Excitotoxicity and motor neurone disease: a review of the evidence. J Neurol Sci 1994;124(suppl):6-13.
8. Zeman S, Lloyd C, Meldrum B, Leigh PN. Excitatory amino acids, free radicals and the pathogenesis of motor neurone disease. Neuropathol Appl Neurobiol 1994;20:219-231.
9. Murphy TH, Schnaar RL, Coyle JT. Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 1990;4:1624-1633.
10. Watkins JC, Evans RH. Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol 1981;21:165-204.
11. Nakanishi S, Masu M. Molecular diversity and functions of glutamate receptors. Annu Rev Biophys Biomol Struct 1994;23:319-348.
12. Schoepp DD, Conn PJ. Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 1993;14:13-20.
13. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995;34:1-26.
14. Garthwaite J, Meldrum BS. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990;11:379-387.
15. Simon RP, Swan JH, Griffiths T, Meldrum BS. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1994;226:850-852.
16. Foster AC, Gill R, Woodruff GN. Neuroprotective effect of MK 801 in vivo. Selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J Neurosci 1988;8:4745-4754.
17. Ascher P, Johnson JW. The NMDA receptor ion channel and its modulation by glycine. In: Watkins JC, Collingridge GL, eds. The NMDA receptor. Oxford: Oxford University Press, 1989:109-121.
18. Hollmann M, Boulter J, Maron C, et al. Zinc potentiates agonist-induced currents at certain splice variants of the NMDA receptor. Neuron 1993;10:943-954.
19. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994;17:31-108.
20. Aizenman E, Reynolds IJ. Modulation of NMDA excitation by redox reagents. Ann NY Acad Sci 1992;648:125-131.
21. + channels as targets for neuroprotective drugs. Trends Pharmacol Sci 1995;16:309-316.
22. Koch RA, Barish ME. Perturbation of intracellular calcium and hydrogen ion regulation in cultured mouse hippocampal neurons by reduction of the sodium ion concentration. J Neurosci 1994;14:2585-2593.
23. Meldrum BS. Excitatory amino acid receptors and their role in epilepsy and cerebral ischemia. Ann NY Acad Sci 1995;757:492-505.
24. Nakanishi N, Axel R, Schneider NA. Alternative splicing generates functionally distinct N-methyl-D-aspartate receptors. Proc Natl Acad Sci USA 1992;89:8552-8556.
25. Kutsuwada T, Mori H, Sakimura K, et al. Molecular diversity of the NMDA receptor channel. Nature 1992;358:36-41.
26. Meguro H, Mori H, Araki K, et al. Functional characterisation of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 1992;357:70-74.
27. Ishii T, Moriyoshi K, Sugihara H, et al. Molecular characterization of the family of N-methyl-D-aspartate receptor subunits. J Biol Chem 1993;268:836-843.
28. Monyer H, Seeburg PH. Molecular biology of glutamate receptor channels. In: Krieglstein J, ed. Pharmacology of cerebral ischemia. Stuttgart: Med Pharm Scientific Publishers 1994:115-117.
29. Burnashev N, Schoepfer R, Monyer H, et al. Control by asparagine residues of calcium permeability and magnesium blockade of the NMDA receptor. Science 1992;257:1415-1419.
30. Laurie DJ, Seeburg PH. Ligand affinities at recombinant N-methyl-D-aspartate receptors depends on subunit composition. Eur J Pharmacol 1994;268:335-345.
31. Williams K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 1993;44:851-859.
32. Williams K, Zappia AM, Pritchett DB, Shen YM, Molinoff PB. Sensitivity of the N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits. Mol Pharmacol 1994;45:803-809.
33. Boulter J, Hollmann M, O'Shea-Greenfield A, et al. Molecular cloning and functional expression of glutamate receptor subunit genes. Science 1990;249:1033-1037.
34. ++ permeability of AMPA type glutamate receptor channels in neocortical neurons caused by differential GluRB subunit expression. Neuron 1994;12:1281-1289.
35. Sommer B, Kohler M, Sprengel R, Seeburg PH. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 1991;67:11-19.
36. Sommer B, Seeburg PH. Glutamate receptor channels: novel properties and new clones. Trends Pharmacol Sci 1992;13:291-296
37. Higuchi M, Single FN, Kohler M, et al. RNA editing of AMPA receptor subunit GluRB: a base-paired intron exon structure determines position and efficiency. Cell 1993;75:1361-1370.
38. Sommer B, Keinanen K, Verdoorn TA, et al. Flip and flop: a cell-specific functional switch in glutamate-operated channels in the CNS. Science 1990;249:1580-1585.
39. Seeburg PH. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci 1993;16:359-365.
40. Rammes G, Swandulla D, Collingridge GL, Hartmann S, Parsons CG. Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. Br J Pharmacol 1996;117:1209-1221.
41. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 1991;14:60-67.
42. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-1624.
43. Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993;364:584.
44. ++ exchanger in anoxic injury of CNS white matter. In: Krieglstein J, Oberpichler-Schwenk H, eds. Pharmacology of cerebral ischaemia. Stuttgart: Wissenschäftliche Verlagsgesellschaft, 1992:13-31.
45. Danbolt NC. The high affinity uptake system for excitatory amino acids in the brain. Prog Neurobiol 1994;44:377-396.
46. Torp R, Danbolt NC, Babaie E, et al. Differential expression of two glial glutamate transporters in the rat brain: an in situ hybridization study. Eur J Neurosci 1994;6:936-942.
47. Arriza JL, Fairman WA, Wadiche JI, et al. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 1994;14:5559-5569.
48. Shashidharan P, Huntley GW, Meyer T, Morrison JH, Plaitakis A. Neuron-specific human glutamate transporter: molecular cloning, characterization and expression in human brain. Brain Res 1994;662:245-250.
49. Rothstein JD, Martin L, Dykes-Hoberg M, Jin L, Levey A, Kuncl RW. Glutamate transporter subtypes: role in excitotoxicity and amyotrophic lateral sclerosis. Ann Neurol 1994;36:282.
50. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic glutamate uptake inhibition produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993;90:6591-6595.
51. Long JB, Rigamonti DD, Oleshanky MA, Wingfield DP, Martinez-Arizala A. Dynorphin A-induced rat spinal cord injury: evidence for excitatory amino acid involvement in a pharmacological model of ischemic spinal cord injury. J Pharmacol Exp Ther 1994;269:358-366.
52. Young AB, Penney JB, Dauth GW, Bromberg MB, Gilman S. Glutamate and aspartate as a possible neurotransmitter of the cerebral cortico-fugal fibres in the monkey. Neurology 1983;33:1513-1516.
53. 3H]AMPA binding by the excitotoxin β-N-oxalyl-α-β-diaminopropionic acid. Eur J Pharmacol 1988;145:357-359.
54. Willis CL, Meldrum BS, Nunn PB, Anderton BH, Leigh PN. Neuronal damage induced by β-N-oxalylamino-L-alanine (BOAA) in rat hippocampus can be prevented by a non-NMDA antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX). Brain Res 1993;627:55-62.
55. Willis CL, Meldrum BS, Nunn PB, Anderton BH, Leigh PN. Neuroprotective effect of free radical scavengers on β-N-oxalylamino-L-alanine (BOAA)-induced neuronal damage in rat hippocampus. Neurosci Lett 1994;182:159-162.
56. Bridges RJ, Hatalski C, Shim SN, Nunn PB. Gliotoxic properties of the lathyrus excitotoxin β-N-oxalyl-L-α,β-diamino-propionic acid (β-L-ODAP). Brain Res 1991;561:262-268.
57. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses. Ann Neurol 1992;31:119-130.
58. Schulz JB, Matthews RT, Henshaw DR, Beal MF. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 1996;71:1043-1048.
59. Monyer H, Giffard RG, Hartley DM, Dugan LL, Goldberg MP, Choi DW. Oxygen or glucose deprivation-induced neuronal injury in cortical cell cultures is reduced by tetanus toxin. Neuron 1992;8:967-973.
60. Rosling H, Tylleskär T. Konzo. In: Shakir RA, Newman PK, Poser CM, eds. Tropical neurology. London: WB Saunders, 1996:353-364.
61. Cavanagh JB. The problems of neurons with long axons. Lancet 1984;1:1284-1287.
62. Steel JC, Williams DB. Calcium and aluminium in the Chamorro diet. In: Leigh PN, Swash M, eds. Motor neuron disease. London: Springer Verlag, 1995;189-200.
63. Meldrum BS. Amino acids as dietary excitotoxins: a contribution to understanding of neurodegenerative disorders. Brain Res Brain Res Rev 1993;18:293-314.
64. Patten BM, Harati Y, Acosta L, Jung S-S, Felmus MT. Free amino acid levels in amyotrophic lateral sclerosis. Ann Neurol 1978;3:305-309.
65. Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987;22:575-579.
66. Perry TL, Hanson S, Jones K. Brain glutamate deficiency in ALS. Neurology 1987;37:1845-1848.
67. Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 1988;24:446-449.
68. Rothstein RH, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
69. Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell HJ. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995;4:209-215.
70. Rothstein JD, Martin LJ, Kuncl RW. Decreased brain and spinal cord glutamate transport in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-1468.
71. 3H]D-aspartate binding sites in the normal human spinal cord and changes in motor neuron disease: a quantitative autoradiographic study. Brain Res 1994;655:195-201.
72. Rothstein JH, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;37:73-84.
73. Bristol LA, Rothstein JD. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann Neurol 1996;39:676-679.
74. Appel SH, Englehardt JI, Smith RG, Stefani E. Theories of causation. In: Swash M, Leigh PN, eds. Motor neurone disease. London: Springer-Verlag, 1995:219-240.
75. Smith RG, Hamilton S, Hofmann F, et al. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med 1992;327:1721-1728.
76. Wierzbicki AS. Antibodies to L-type calcium channels in amyotrophic lateral sclerosis. New Engl J Med 1993;328:1355-1356.
77. Lennon V, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474.
78. Smith RG, Alexianu ME, Crawford G, Nyormoi O, Stefani E, Appel SH. The cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. Proc Natl Acad Sci USA 1994;91:3393-3397.
79. Siklós L, Engelhardt J, Harati Y, Smith RG, Joó F, Appel SH. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann Neurol 1996;29:203-216.
80. 3H]MK 801 binding sites in the normal human spinal cord. Brain Res 1991;539:164-168.
81. 3H]MK 801 binding sites in the normal human brainstem in relation to motor neuron disease. Brain Res 1992;637:276-280.
82. Ince PG, Stout N, Shaw PJ, et al. Parvalbumin and calbindin D-28K in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol 1993;19:291-299.
83. Brown RH. Superoxide dismutase and familial amyotrophic lateral sclerosis: new insights into mechanisms and treatments [editorial]. Ann Neurol 1996;39:145-146.
84. Radunovic A, Leigh PN. Cu/Zn superoxide dismutase gene mutations in ALS: correlation between genotype and clinical features. J Neurol Neurosurg Psychiatry 1996 (in press).
85. Al-Chalabi A, Powell JF, Leigh PN. Neurofilaments, free radicals, excitotoxins and amyotrophic lateral sclerosis. Muscle Nerve 1995;18:540-545.
86. Coyle JT, Putfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-695.
87. Gurney ME, Cutting FB, Ahai P, et al. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.